Jointown Pharmaceutical Group Co., Ltd

SHSE:600998 Stock Report

Market Cap: CN¥25.7b

Jointown Pharmaceutical Group Valuation

Is 600998 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600998 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600998 (CN¥5.21) is trading above our estimate of fair value (CN¥0.19)

Significantly Below Fair Value: 600998 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600998?

Key metric: As 600998 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600998. This is calculated by dividing 600998's market cap by their current earnings.
What is 600998's PE Ratio?
PE Ratio12.5x
EarningsCN¥2.05b
Market CapCN¥25.69b

Price to Earnings Ratio vs Peers

How does 600998's PE Ratio compare to its peers?

The above table shows the PE ratio for 600998 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.6x
600511 China National Medicines
12x9.1%CN¥26.4b
600056 China Meheco Group
19.3xn/aCN¥17.5b
000028 China National Accord Medicines
11.1x6.2%CN¥15.3b
301015 Qingdao Baheal Medical
20x21.2%CN¥13.9b
600998 Jointown Pharmaceutical Group
12.5x17.1%CN¥25.7b

Price-To-Earnings vs Peers: 600998 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (15.6x).

Price to Earnings Ratio vs Industry

How does 600998's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600998 12.5xIndustry Avg. 32.8xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600998 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the CN Healthcare industry average (32.8x).

Price to Earnings Ratio vs Fair Ratio

What is 600998's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600998 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.5x
Fair PE Ratio25.4x

Price-To-Earnings vs Fair Ratio: 600998 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the estimated Fair Price-To-Earnings Ratio (25.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600998 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥5.21
CN¥6.41
+23.1%
30.9%CN¥8.60CN¥3.80n/a3
Nov ’25CN¥5.24
CN¥7.38
+40.8%
32.4%CN¥10.26CN¥3.80n/a4
Oct ’25CN¥5.74
CN¥7.45
+29.8%
32.7%CN¥10.26CN¥3.80n/a4
Sep ’25CN¥4.66
CN¥7.69
+64.9%
31.6%CN¥10.26CN¥4.11n/a4
Aug ’25CN¥4.47
CN¥7.86
+75.7%
30.4%CN¥10.26CN¥4.11n/a4
Jul ’25CN¥5.01
CN¥7.86
+56.8%
30.4%CN¥10.26CN¥4.11n/a4
Jun ’25CN¥5.74
CN¥7.90
+37.6%
29.5%CN¥10.26CN¥4.26n/a4
May ’25CN¥6.36
CN¥7.90
+24.1%
29.5%CN¥10.26CN¥4.26n/a4
Apr ’25CN¥6.26
CN¥5.89
-5.9%
27.6%CN¥7.52CN¥4.26n/a2
Mar ’25CN¥6.20
CN¥5.89
-5.0%
27.6%CN¥7.52CN¥4.26n/a2
Feb ’25CN¥5.36
CN¥5.89
+10.0%
27.6%CN¥7.52CN¥4.26n/a2
Jan ’25CN¥5.43
CN¥5.89
+8.4%
27.6%CN¥7.52CN¥4.26n/a2
Dec ’24CN¥5.80
CN¥5.97
+2.9%
26.0%CN¥7.52CN¥4.42n/a2
Nov ’24CN¥5.60
CN¥5.97
+6.5%
26.0%CN¥7.52CN¥4.42CN¥5.242
Oct ’24CN¥6.00
CN¥6.66
+11.1%
33.1%CN¥8.87CN¥4.46CN¥5.742
Sep ’24CN¥5.56
CN¥6.66
+19.8%
33.1%CN¥8.87CN¥4.46CN¥4.662
Aug ’24CN¥5.34
CN¥5.95
+11.4%
25.1%CN¥7.44CN¥4.46CN¥4.472
Jul ’24CN¥5.75
CN¥5.95
+3.5%
25.1%CN¥7.44CN¥4.46CN¥5.012
Jun ’24CN¥5.89
CN¥5.80
-1.5%
28.3%CN¥7.44CN¥4.16CN¥5.742
May ’24CN¥6.16
CN¥5.80
-5.8%
28.3%CN¥7.44CN¥4.16CN¥6.362
Apr ’24CN¥5.55
CN¥5.40
-2.7%
23.0%CN¥6.64CN¥4.16CN¥6.262
Mar ’24CN¥5.40
CN¥4.74
-12.2%
12.2%CN¥5.31CN¥4.16CN¥6.202
Feb ’24CN¥4.95
CN¥4.74
-4.2%
12.2%CN¥5.31CN¥4.16CN¥5.362
Jan ’24CN¥4.85
CN¥4.74
-2.2%
12.2%CN¥5.31CN¥4.16CN¥5.432
Dec ’23CN¥5.02
CN¥4.74
-5.6%
12.2%CN¥5.31CN¥4.16CN¥5.802
Nov ’23CN¥4.73
CN¥4.74
+0.2%
12.2%CN¥5.31CN¥4.16CN¥5.602

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.77

7D

-3.4%

1Y

-34.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

7D

5.4%

1Y

-14.7%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.72

7D

2.3%

1Y

36.8%